Toxin

(redirected from Botulinum toxin type a)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
Related to Botulinum toxin type a: botulinum toxin, Botulinum Toxin Injections

Toxin

Any poisonous substance a living thing produces as part of its metabolic or other natural process. That is, toxins themselves are not living things, but are produced by living things. Toxins are defined by the Biological Weapons Convention.
Mentioned in ?
References in periodicals archive ?
38) For this reason, we have confined our review to a single botulinum toxin type A preparation (BOTOX[TM]; Allergan), which has been examined in a large number of published studies; doses refer specifically to this product.
Repeated botulinum toxin type A injections to treat patients with Frey syndrome.
The BOTOX(R) trademark identifies the botulinum toxin type A purified neurotoxin complex product manufactured and sold by Allergan.
Chana, Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study.
002), reflecting the positive effects of botulinum toxin type A on urinary incontinence signs and symptoms.
Botox is the only botulinum toxin type A approved for use in humans in the United States.
Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use.
About AI-09 AI-09, Botulinum Toxin Type A, For Injection, is an investigational product being developed for FDA-approved clinical indications for injectable botulinum.
Merz Pharma Receives Approval for Botulinum Toxin Type A II-39
Flynn's presentation titled "Differentiating Botulinum Toxin Type A Preparations: Basic and Clinical Science" at the annual meeting of The American Academy of Dermatology in Denver on March 24[sup.
Anterios is currently conducting Phase 2b clinical trials studying ANT-1207, a patented topical botulinum toxin type A treatment.
We believe the application of botulinum toxin type A without an injection using Revance's MTS technology, as well as the development of new botulinum toxin molecules, will be of interest globally and play a major role in the development of new non-invasive treatment alternatives.